AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
Enhertu data will show the potential to improve survival for metastatic breast cancer patients and define a new segment of HER2-low disease.Results from multiple trials further reinforce strength of industry-leading portfolio and pipeline, including novel combinations, across cancers with high unmet need.AstraZeneca advances its ambition to redefine cancer care with new data to be presented across its diverse and industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, 3 to 7 June 2022. A total of 18 approved and potential new